Associated Genetic Biomarkers

Overview

NCI Definition: An adenocarcinoma arising from the thyroid gland showing only limited evidence of follicular cell differentiation. Microscopically, the adenocarcinoma cells are arranged in insular, solid, and trabecular patterns. There is associated necrosis, and vascular invasion. The prognosis depends on the tumor stage, complete or partial surgical removal of the tumor, and the degree of response to radioactive iodine therapy (adapted from WHO Tumors of Endocrine Organs, IARC Press, Lyon 2004) [1]

Poorly differentiated thyroid gland carcinomas most frequently harbor alterations in NRAS, BRAF, TP53, PTEN, and CDKN2A [2].

Most Commonly Altered Genes in Poorly Differentiated Thyroid Gland Carcinoma

NRAS Mutation, NRAS Exon 3 Mutation, NRAS Exon 3 Missense, NRAS Codon 61 Missense, and NRAS Q61R are the most common alterations in poorly differentiated thyroid gland carcinoma [2].

Top Alterations in Poorly Differentiated Thyroid Gland Carcinoma

Significant Genes in Poorly Differentiated Thyroid Gland Carcinoma

ACBD5 +

AFAP1L2 +

ARAF +

BRAF +

CCDC6 +

CEP43 +

CRKL +

ERC1 +

GOLGA5 +

HOOK3 +

HRAS +

KIAA1217 +

KIF5B +

KRAS +

MAP2K1 +

MAP2K2 +

MAP2K4 +

MAP3K1 +

MAPK1 +

NCOA4 +

NF1 +

NF2 +

NRAS +

PPFIBP2 +

PRKAR1A +

RAF1 +

RET +

RUFY1 +

SRC +

TFG +

TRIM27 +

Disease Details

Synonyms
Thyroid Gland Poorly Differentiated Carcinoma, Poorly Differentiated Carcinoma of Thyroid Gland, High-grade poorly differentiated carcinoma, c/w thyroid primary, Insular Carcinoma, Poorly Differentiated Carcinoma of the Thyroid Gland, Poorly Differentiated Thyroid Gland Cancer, Poorly Differentiated Thyroid Carcinoma
Parent(s)
Thyroid Gland Adenocarcinoma
OncoTree Name
Poorly Differentiated Thyroid Cancer
OncoTree Code
THPD

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.